Replies to post #511994 on NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

The failure rate of Phase 3 trial for approvals is ~40%. The primary reason:
"The reasons for these failures appear to be unchanged: 75 to 80% are due to problems with efficacy and/or safety."

NWBO's questionable manipulated trial data, complete confounding of the naive OS, post hoc data dredged recurrent OS arm (n=64) -- Good luck boys.